Bionano Genomics, Inc. has taken a significant step by filing a new registration statement with the Securities and Exchange Commission. This filing, dated October 27, 2026, is aimed at ensuring that the exercise of certain outstanding warrants is covered under the registration statement. This move is crucial as it highlights the company's commitment to securing capital and potentially expanding its operations.

The registration statement indicates that Bionano intends to register a total of 1,332,632 shares of its common stock, which can be issued upon the exercise of various warrants. These include:

• 661,377 shares from 2025 Purchase Warrants with an exercise price of $15.120 per share.

• 164,684 shares from Series C Warrants with an exercise price of $18.234 per share.

• 145,560 shares from 2024 Purchase Warrants with an exercise price of $61.20 per share.

• 361,011 shares from 2023 Purchase Warrants with an exercise price of $191.13 per share.

This filing is particularly important as it comes ahead of the expiration of Bionano's previous registration statement, which is set to expire on November 6, 2026. By ensuring that these warrants remain exercisable, Bionano is positioning itself to maintain flexibility in its capital structure.

Background

Bionano Genomics, Inc., incorporated in Delaware, operates in the laboratory analytical instruments sector (SIC 3826). The company trades under the ticker symbol BNGO on the Nasdaq exchange. Bionano has been focused on advancing its genomic analysis technologies, which are crucial for various applications in research and clinical settings.

In recent filings, Bionano has shown a proactive approach to managing its financial resources. On October 19, 2026, the company filed a Schedule 13G, indicating ongoing interest from investors. Additionally, on September 14, 2026, it filed an 8-K, demonstrating its commitment to transparency and regulatory compliance.

What the Filing Says

The filing states that the registration statement is being made solely to ensure that the exercise of the outstanding warrants is covered. It emphasizes that the company is taking necessary steps to maintain its capital-raising capabilities.

Impact

This filing may have implications for Bionano's stakeholders, including current and potential investors, as well as competitors in the laboratory analytical instruments industry. By securing the ability to exercise these warrants, Bionano could enhance its liquidity and financial stability, which may influence investor confidence and market dynamics.

What's Next

The filing does not specify what happens next. However, Bionano's management will likely continue to monitor market conditions and investor interest as they prepare for future capital-raising efforts.